IAS 2023: Update to navigate the programme and online access
1 August 2023. Related: Conference reports.
Conference reports
WHO endorses “zero” transmission risk for people with HIV with an undetectable viral load
1 August 2023. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
Viral load level when suppressed <1000 predicts future rebound: 3-monthly monitoring required
1 August 2023. Related: Conference reports, HIV prevention and transmission.
ART-associated hypertension can be successfully treated in African settings
1 August 2023. Related: Conference reports, Side effects, Coinfections and complications.
REPRIEVE study: statin benefits people living with HIV at low to moderate CVD risk
1 August 2023. Related: Conference reports, Coinfections and complications.
Geneva patient and other HIV cure research at IAS 2023
1 August 2023. Related: Conference reports, Cure-related research.
Guide to other HIV cure-related research at IAS 2023
1 August 2023. Related: Conference reports.
Rapporteur summaries: track B clinical science
1 August 2023. Related: Conference reports, Antiretrovirals.
Early press conference: cure, gay circumcision, PrEP choices, mpox, and COVID-19
1 August 2023. Related: Conference reports, mpox (monkeypox), HIV prevention and transmission, Cure-related research, COVID-19: HIV and COVID-19 coinfection, COVID-19.
High rates of occult HBV in Botswana: risks from relying on HBsAg screening
1 August 2023. Related: Conference reports, Hepatitis coinfection.
Anal cancer: 1 in 5 risk of missing precancerous lesions if only HSIL are biopsied
1 August 2023. Related: Conference reports, Cancer and HIV.
29th BHIVA Annual Conference 2023 (BHIVA 2023) – final reports
1 August 2023. Related: Conference reports.
No vertical HIV transmissions in the UK from women eligible for supported breastfeeding
1 August 2023. Related: Conference reports, Pregnancy, Paediatric care.
Adverse birth outcomes with diabetes and hypertensive disorders in pregnancy
1 August 2023. Related: Conference reports, Pregnancy.
BHIVA Annual Conference 2023 (BHIVA 2023)
1 June 2023. Related: Conference reports.
UK cascade data cautions UNAIDS 95:95:95 targets: re-engaging people in care
1 June 2023. Related: Conference reports, Treatment strategies, Treatment advocacy.
Overview of weight gain, integrase inhibitors and ART
1 June 2023. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Selected webcasts from BHIVA 2023
1 June 2023. Related: Conference reports, Treatment strategies, Side effects, Lipodystrophy and metabolic complications.
30th CROI (CROI 2023): final reports
1 June 2023. Related: Conference reports.
Viral reservoir increases on long-term ART: new strategies for a cure
1 June 2023. Related: Conference reports, Cure-related research.
Microbiota biomarkers might predict risk of HSIL progression: succinyl-CoA and cobalamin
1 June 2023. Related: Conference reports, Cancer and HIV.
CROI overviews by BHIVA and IAS-USA
1 June 2023. Related: Conference reports.
30th CROI (CROI 2023): further reports
6 April 2023. Related: Conference reports.
Dapivirine ring safe in late pregnancy and during breastfeeding
6 April 2023. Related: Conference reports.
Implications of restrictions on reproductive rights for HIV care in the USA and beyond
6 April 2023. Related: Conference reports, Treatment access, Women's health, Pregnancy.
30th Conference on Retroviruses and OIs (CROI 2023): first reports
10 March 2023. Related: Conference reports.
CROI 2023: Pipeline HIV drugs and formulations for treatment and PrEP
10 March 2023. Related: Conference reports, Antiretrovirals.
CROI 2023: Six-monthly ART – lenacapavir + dual bNAbs maintains undetectable viral load for 26 weeks after single doses
10 March 2023. Related: Conference reports, Antiretrovirals.
CROI 2023: Other lenacapavir studies – experienced and naive updates, the dosing window, HIV-2 and PrEP
10 March 2023. Related: Conference reports, Antiretrovirals.
CROI 2023: Similar PK profile for thigh vs gluteal CAB/RPV-LA injections: accidental intravenous injection
10 March 2023. Related: Conference reports, Antiretrovirals.
CROI 2023: Efficacy of N6LS monotherapy correlated with baseline factors
10 March 2023. Related: Conference reports, Antiretrovirals.
CROI 2023: CAB/RPV-LA levels are not reduced after switching from efavirenz
10 March 2023. Related: Conference reports, PK and drug interactions.
CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study
10 March 2023. Related: Conference reports, Treatment strategies, Drug resistance.
CROI 2023: Point-of-care testing for mothers and infants: results from the LIFE study
10 March 2023. Related: Conference reports, Pregnancy, Paediatric care.
CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young adults
10 March 2023. Related: Conference reports, Side effects, HIV prevention and transmission.
CROI 2023: Single dose doxycycline as PEP for STIs (doxy-PEP): five studies
10 March 2023. Related: Conference reports, Coinfections and complications.
CROI 2023: Severe mpox outcomes with a low CD4 count and detectable viral load: a new AIDS-defining condition?
10 March 2023. Related: Conference reports, mpox (monkeypox).
30th Conference on Retroviruses and Opportunistic Infection (CROI 2023)
1 February 2023. Related: Conference reports.
Glasgow HIV Congress (2022)
1 February 2023. Related: Conference reports.
Glasgow 2022: pipeline studies with bNAbs N6LS and maturation inhibitor GSK254
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: doravirine updates
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: long-acting cabotegravir/rilpivirine: adverse events, implementation and PROMs
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: community statement on HIV and ageing
1 February 2023. Related: Conference reports, Ageing and life expectancy, Treatment advocacy.
Glasgow HIV Congress 2022
1 December 2022. Related: Conference reports.
Glasgow 2022: Better re-suppression after viral rebound with DTG-based ART compared to EFV- or PI-based regimens
1 December 2022. Related: Conference reports, Treatment strategies.
Glasgow 2022: Vertical transmission rate below 0.3% among women living with HIV in the UK
1 December 2022. Related: Conference reports, Pregnancy.
Glasgow 2022: Impact of islatravir on lymphocyte counts in a dose-ranging study: a post-hoc analysis
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Islatravir studies to use 0.25 mg daily dose to overcome risk of reducing CD4 and total lymphocytes
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Fostemsavir 240 week results from BRIGHTE study
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Fostemsavir: QT prolongation and drug-drug interactions
1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Mpox updates on epidemiology, treatment and prevention
1 December 2022. Related: Conference reports, mpox (monkeypox).
24th International AIDS Conference (AIDS 2022): Final report
1 December 2022. Related: Conference reports.
IAS 2022: Metabolic complications of newer HIV drugs in older people
1 December 2022. Related: Conference reports, Lipodystrophy and metabolic complications.
14th International Workshop on HIV & Pediatrics
3 October 2022. Related: Conference reports.
First paediatric pharmacokinetic data of dolutegravir in combination with a TAF-based NRTI backbone
3 October 2022. Related: Conference reports, Paediatric care.
24th International AIDS Conference (AIDS 2022): further reports
3 October 2022. Related: Conference reports.
AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3
3 October 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
AIDS 2022: Gender-affirming hormones, weight gain and ART
3 October 2022. Related: Conference reports, PK and drug interactions, Side effects.
24th International AIDS Conference (AIDS 2022)
1 September 2022. Related: Conference reports.
Dolutegravir no longer linked to higher risk of neural tube defects: latest update from the Tsepamo study
1 September 2022. Related: Conference reports, Pregnancy.
Weight gain with dolutegravir and TAF in ADVANCE study continues out to week 192
1 September 2022. Related: Conference reports, Women's health.
VRC01 added to early ART in infants did not reduce viral reservoir
1 September 2022. Related: Conference reports, Paediatric care.
Using PrEP during pregnancy is safe for children
1 September 2022. Related: Conference reports, Pregnancy, Paediatric care.
Long-acting CAB/RPV injections have a similar weight and lipid profile to dolutegravir-based oral ART
1 September 2022. Related: Conference reports.
Montreal’s response to monkeypox: rapid vaccine rollout, 39 breakthrough infections
1 September 2022. Related: Conference reports, mpox (monkeypox).